Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Pro Medicus Limited ( (AU:PME) ) has shared an announcement.
Pro Medicus Limited has announced an update regarding its ongoing on-market buy-back program, with a recent purchase of 2,100 ordinary fully paid securities, bringing the total bought back to 43,224. This buy-back initiative reflects the company’s strategy to manage its capital structure and potentially enhance shareholder value.
The most recent analyst rating on (AU:PME) stock is a Buy with a A$350.00 price target. To see the full list of analyst forecasts on Pro Medicus Limited stock, see the AU:PME Stock Forecast page.
More about Pro Medicus Limited
Pro Medicus Limited operates in the healthcare technology industry, providing advanced imaging solutions and services. The company focuses on delivering innovative medical imaging software and services to healthcare providers, enhancing diagnostic capabilities and operational efficiencies.
YTD Price Performance: -6.09%
Average Trading Volume: 175,674
Technical Sentiment Signal: Buy
Current Market Cap: A$24.5B
For a thorough assessment of PME stock, go to TipRanks’ Stock Analysis page.